Psoriasis vulgaris - Pipeline Insight, 2024

This “Psoriasis vulgaris - Pipeline Insight, 2024,” report provides comprehensive insights about 40+ companies and 45+ pipeline drugs in Psoriasis vulgaris pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Psoriasis vulgaris Understanding

Psoriasis vulgaris: Overview

Psoriasis vulgaris is a chronic skin disorder characterized by the rapid turnover of the epidermis, resulting in the accumulation of thick scale over sites of frequent trauma and irritation. Psoriasis vulgaris is commonly known as chronic plaque psoriasis or plaque psoriasis, characterized by raised, red skin plaques with silvery scales. It is the most common form of psoriasis, affecting between 80-90% of people with psoriasis. Psoriasis is a clinically heterogeneous lifelong skin disease that presents in multiple forms such as plaque, flexural, guttate, pustular, or erythrodermic. The classic skin lesions of psoriasis vulgaris can be described as sharply demarcated, scaly, erythematous plaques often found on the extensor surfaces. Psoriasis is not curable, but it is treatable, and people who think they have psoriasis vulgaris should seek medical attention to confirm the diagnosis and begin treatment as soon as possible.

The pathophysiology of psoriasis is characterized by excessive epidermal growth and altered keratinocyte differentiation. The underlying pathogenesis is multifactorial and complex with genetic, immunologic, and environmental contributions. Certain environmental triggers are thought to disrupt the homeostasis of the skin immune system in genetically predisposed individuals. Medications implicated in the induction and exacerbation of psoriasis include angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), antimalarials, lithium, and nonsteroidal anti-inflammatory drugs.

Psoriasis vulgaris is diagnosed primarily through a physical examination of the skin, scalp, and nails for signs of the condition. The doctor may also ask questions about the patient's health, medical and family history, recent illnesses, and severe stress. In some cases, a small skin sample may be taken for examination under a microscope to rule out other skin conditions that look like psoriasis and to determine the type of psoriasis. A skin biopsy is seldom required for diagnosis.

Psoriasis vulgaris - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Psoriasis vulgaris pipeline landscape is provided which includes the disease overview and Psoriasis vulgaris treatment guidelines. The assessment part of the report embraces, in depth Psoriasis vulgaris commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Psoriasis vulgaris collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Psoriasis vulgaris R&D. The therapies under development are focused on novel approaches to treat/improve Psoriasis vulgaris.

Psoriasis vulgaris Emerging Drugs Chapters

This segment of the Psoriasis vulgaris report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Psoriasis vulgaris Emerging Drugs

BAT2306: Bio-Thera SolutionsBAT2306 is a biosimilar drug candidate to Cosentyx (secukinumab). Secukinumab is approved for the treatment of plaque psoriasis, psoriatic arthritis, ankylosing spondylitis (AS, radiographic axial spondyloarthritis) and non-radiographic axial spondyloarthritis (nr-axSpA). In China, Secukinumab is approved for the treatment of plaque psoriasis and ankylosing spondylitis. Secukinumab selectively targets Interleukin 17A (IL-17A). IL-17A, produced mainly by a subset of T helper cells, named Th17, as well as other T cells, neutrophils and mast cells, promotes the expression of other pro-inflammatory cytokines and effector proteins, leading to the activation of neutrophils and macrophages as well as epithelial cells and fibroblasts. The drug is currently in Phase III stage of its clinical development for the treatment of Plaque Psoriasis.

SGX302: SoligenixSGX302 is a photodynamic light therapy for psoriasis treatment which uses synthetically manufactured hypericin applied as an ointment and activated with visible fluorescent light. Hypericin is one of the most photoactive compounds known that is easily activated with relatively low energy light. Hypericin, the active ingredient in SGX302, is absorbed by cells in the treated skin and can then be activated by fluorescent light. The drug is currently in Phase II stage of its clinical development for the treatment of Psoriasis vulgaris.

CAN10: Cantargia ABCantargia is developing CAN10, which is an antibody. IL1RAP plays an important role in inflammatory processes and is necessary for transferring signals from the IL-1 molecule as well as the IL-33 and IL-36 molecules. These can trigger inflammation and play a central role in several autoimmune and inflammatory disorders. CAN10 antibody by binding IL1RAP, can block all these signaling pathways simultaneously. This function provides CAN10 with great potential for treatment of several diseases where CAN10 could achieve a broader and stronger effect compared to treatments aimed at the individual signaling pathways. The drug is currently in Phase I stage of its clinical development for the treatment of Psoriasis vulgaris.

XmAb564: XencorXmAb564 is a monovalent IL2-Fc fusion protein, engineered to selectively activate and expand Tregs for the potential treatment of patients with autoimmune diseases. Interleukin-2 (IL-2) is an immune signaling protein that activates and expands certain immune cell populations, including regulatory T cells (Tregs). Tregs prevent autoimmunity by suppressing other immune cells from attacking normal tissue; however, in many autoimmune diseases, Tregs become dysregulated. XmAb564 is engineered with reduced binding affinity for IL-2’s beta receptor (IL-2Rß, CD122) and increased binding affinity for its alpha receptor (IL-2Ra, CD25). Xencor’s XmAb Bispecific Fc Domain additionally provides a stable protein scaffold and improves XmAb564’s pharmacologic properties. The drug is currently in Phase I stage of its clinical development for the treatment of Psoriasis vulgaris.

Psoriasis vulgaris: Therapeutic Assessment

This segment of the report provides insights about the different Psoriasis vulgaris drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Psoriasis vulgaris

There are approx. 40+ key companies which are developing the therapies for Psoriasis vulgaris. The companies which have their Psoriasis vulgaris drug candidates in the most advanced stage, i.e. phase III include, Bio-Thera Solutions.

Phases

This report covers around 45+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Psoriasis vulgaris pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Psoriasis vulgaris: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Psoriasis vulgaris therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Psoriasis vulgaris drugs.

Psoriasis vulgaris Report Insights

• Psoriasis vulgaris Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Psoriasis vulgaris Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Psoriasis vulgaris drugs?
• How many Psoriasis vulgaris drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Psoriasis vulgaris?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Psoriasis vulgaris therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Psoriasis vulgaris and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Xencor
• Ono Pharmaceutical Co. Ltd
• Boehringer Ingelheim
• GC Cell Corporation
• Soligenix
• Cantargia AB
• Huabo Biopharm
• Huaota Biopharmaceuticals
• Bio-Thera Solutions
• Hangzhou Highlightll Pharmaceutical
• Sanofi
• Meiji Pharma

Key Products

• XmAb564
• BAT-2306
• ONO-4685
• BI 765250
• CT303
• SGX302
• CAN10
• HB0017
• HOT-3010
• TLL018
• SAR441566
• ME3183

This product will be delivered within 1-3 business days.